Discordant Protein and mRNA Expression in Lung Adenocarcinomas*

Guoan Chen‡, Tarek G. Gharib‡, Chiang-Ching Huang§, Jeremy M. G. Taylor§, David E. Misek¶, Sharon L. R. Kardia¶, Thomas J. Giordano**, Mark D. Iannettoni‡, Mark B. Orringer‡, Samir M. Hanash¶, and David G. Beer‡ ¶§

The relationship between gene expression measured at the mRNA level and the corresponding protein level is not well characterized in human cancer. In this study, we compared mRNA and protein expression for a cohort of genes in the same lung adenocarcinomas. The abundance of 165 protein spots representing 98 individual genes was analyzed in 76 lung adenocarcinomas and nine non-neoplastic lung tissues using two-dimensional polyacrylamide gel electrophoresis. Specific polypeptides were identified using matrix-assisted laser desorption/ionization mass spectrometry. For the same 85 samples, mRNA levels were determined using oligonucleotide microarrays, allowing a comparative analysis of mRNA and protein expression among the 165 protein spots. Twenty-eight of the 165 protein spots (17%) or 21 of 98 genes (21.4%) had a statistically significant correlation between protein and mRNA expression (r = 0.2445; p < 0.05); however, among all 165 proteins the correlation coefficient values (r) ranged from −0.467 to 0.442. Correlation coefficient values were not related to protein abundance. Further, no significant correlation between mRNA and protein expression was found (r = −0.025) if the average levels of mRNA or protein among all samples were applied across the 165 protein spots (98 genes). The mRNA/protein correlation coefficient also varied among proteins with multiple isoforms, indicating potentially separate isoform-specific mechanisms for the regulation of protein abundance. Among the 21 genes with a significant correlation between mRNA and protein, five genes differed significantly between stage I and stage III lung adenocarcinomas. Using a quantitative analysis of mRNA and protein expression within the same lung adenocarcinomas, we showed that only a subset of the proteins exhibited a significant correlation with mRNA abundance.

Molecular & Cellular Proteomics 1:304–313, 2002.

Lung cancer is the leading cause of cancer death for both men and women in the United States. Adenocarcinomas of the lung comprise ~40% of all new cases of non-small cell lung cancer and are now the most common histologic type. Functional genomics, broadly defined as the comprehensive analysis of genes and their products, have become a recent focus of the life sciences (1). Application of these approaches to lung adenocarcinomas has the potential to aid in the identification of high risk patients with resectable early stage lung cancer that may benefit from adjuvant therapy, as well as to identify new therapeutic targets. In human lung cancer, however, little is currently understood regarding the relationship between gene expression as determined by measuring mRNA levels and the corresponding abundance of the protein products.

A number of powerful techniques for analysis of gene expression have been used including differential display (2), serial analysis of gene expression (3), DNA microarrays (4), and proteomics via two-dimensional polyacrylamide gel electrophoresis and mass spectrometry (5). Bioinformatics tools have also been developed to help determine quantitative mRNA/protein expression profiles of all types of cells and tissues (6) and now can be applied to benign and malignant tumors. DNA microarrays (cDNA and oligonucleotide) permit the parallel assessment of thousands of genes and have been utilized in gene expression monitoring (7), polymorphism analysis (8), and DNA sequencing (9). Recent studies have focused on classification or identification of subgroups of lung tumors using DNA microarrays (10, 11). The use of mRNA expression patterns by themselves, however, is insufficient for understanding the expression of protein products, as additional post-transcriptional mechanisms, including protein translation, post-translational modification, and degradation, may influence the level of a protein present in a given cell or tissue. Proteomic analyses, a complementary technology to DNA microarrays for monitoring gene expression, involves protein separation and quantitative assessment of protein spots using 2D1-PAGE and protein identification using mass spectrometry. By combining proteomic and transcriptional analyses of the same samples, however, it may be possible to understand the complex mechanisms influencing protein expression in human cancer.

In this study, we determined mRNA and protein levels for 165 proteins (98 genes) in 76 lung adenocarcinomas and nine

---

1 The abbreviations used are: 2D, two-dimensional; MALDI-MS, matrix-assisted laser desorption/ionization mass spectrometry.
**TABLE I**

Correlation coefficients of protein and mRNA where only one spot was present on 2D gels

$r^*$, correlation coefficient value $> 0.2445$; $p < 0.05$. Values in boldface are significant at $p < 0.05$.

| Spot  | Unigene | Gene name | $r^*$  | Protein name                                      |
|-------|---------|-----------|--------|--------------------------------------------------|
| 1104  | Hs.184510 | SFN       | 0.4337 | 14-3-3 α                                         |
| 0994  | Hs.77840  | ANXA4     | 0.4219 | Annexin IV                                       |
| 1314  | Hs.10958  | DJ-1      | 0.3982 | DJ-1 protein/MER5                                 |
| 1454  | Hs.75428  | SOD1      | 0.3863 | Superoxide dismutase (Cu-Zn)                     |
| 1638  | Hs.227751 | LGALS1    | 0.3318 | Galectin 1                                       |
| 0264  | Hs.129548 | HNRPK     | 0.3034 | Transformation up-regulated nuclear protein      |
| 1405  | Hs.111334 | FTLP      | 0.2849 | Ferritin light chain                              |
| 0963  | Hs.300711 | ANXA5     | 0.2468 | Annexin V                                        |
| 1252  | Hs.4745   | PSMC      | 0.2445 | 26 S proteasome p28                               |
| 0906  | Hs.234489 | LDHB      | 0.4420 | L-lactate dehydrogenase H chain (LDH-B)           |
| 1171  | Hs.241515 | COX11     | 0.2310 | COX 11                                           |
| 1160  | Hs.181013 | PGAM1     | 0.2023 | Phosphoglycerate mutase                          |
| 0759  | Hs.74635  | DLD       | 0.1965 | Dihydrolipoamide dehydrogenase precursor         |
| 1193  | Hs.83383  | AOE372    | 0.1932 | Antioxidant enzyme AOE372                        |
| 0172  | Hs.3069   | HSPA9B    | 0.1872 | GRP75                                            |
| 0777  | Hs.979    | PDHB      | 0.1855 | Pyruvate dehydrogenase E1-β subunit precursor    |
| 1249  | Hs.226795 | GSTP1     | 0.1773 | Glutathione S-transferase pi (GST-pi)            |
| 1685  | Hs.76136  | TXN       | 0.1732 | Thoredoxin                                       |
| 1205  | Hs.82314  | HPRT1     | 0.1589 | HG phosphoribosyltransferase                     |
| 1230  | Hs.279860 | TPT1      | 0.1466 | Translationally controlled tumor protein (TCTP)   |
| 0603  | Hs.181357 | LAMR1     | 0.1463 | LAMR                                             |
| 1358  | Hs.28914  | APRT      | 0.1399 | Adenine phosphoribosyl transferase               |
| 1410  | Hs.82113  | DUT       | 0.1213 | dUTP pyrophosphatase (dUTPase)                   |
| 1825  | Hs.112378 | LIMS1     | 0.1213 | Pinch-2 protein                                  |
| 0871  | Hs.250502 | CA8       | 0.1122 | Carbonic anhydrase-related protein; Syntaxin     |
| 0289  | Hs.82916  | CCT6A     | 0.1106 | Chaperonin-like protein                          |
| 1143  | Hs.11465  | GSTT1p28  | 0.0997 | Glutathione S-transferase homolog (GST homolog)  |
| 1456  | Hs.118638 | NME1      | 0.0932 | Nm23 (NDPKA)                                     |
| 1598  | Hs.278503 | RIG       | 0.0905 | RIIG (U32331)                                    |
| 1354  | Hs.89761  | ATP5D     | 0.0904 | FIFO-type ATP synthase subunit d                 |
| 1445  | Hs.155485 | HIP2      | 0.0843 | Huntingtin interacting protein 2 (HIP2)          |
| 1479  | Hs.177486 | APP       | 0.0746 | Amyloid B4A                                      |
| 0608  | Hs.182285 | KRT19     | 0.0439 | Cytokeratin 19                                   |
| 1071  | Hs.10842  | RAN       | 0.0277 | GTP-binding nuclear protein RAN(TC4)             |
| 0991  | Hs.297939 | CTSB      | 0.0254 | Cathepsin B                                      |
| 0842  | Hs.77274  | PLAU      | 0.0248 | Urokinase plasminogen activator                  |
| 0923  | Hs.199248 | B4GALT1   | 0.0183 | β 1,4-galactosyl transferase                     |
| 0613  | Hs.1247   | AP0A4     | 0.0176 | Apolipoprotein A4 (ApoA4)                        |
| 1338  | Hs.104413 | CLTA      | 0.0123 | Clathrin light chain A                           |
| 0902  | Hs.5123   | SID6–306  | 0.0117 | Cytosolic inorganic pyrophosphatase              |
| 1688  | Hs.1473   | GRP       | −0.0040 | Preprogastrin-releasing peptide                  |
| 0265  | Hs.274402 | HSPA1B    | −0.0071 | Heat shock-induced protein                       |
| 1414  | Hs.77541  | ARF5      | −0.0096 | ADP-ribosylation factor 1                        |
| 0710  | Hs.97206  | HIP1      | −0.0114 | Huntingtin interacting protein 1 (HIP1)          |
| 0532  | Hs.170328 | MSN       | −0.0132 | Meso(E)                                          |
| 0525  | Hs.284255 | ALPP      | −0.0148 | Alkaline phosphate, placental                    |
| 0513  | Hs.76901  | PDIF      | −0.0289 | Protein disulfide isomerase-related protein 5    |
| 1659  | Hs.256697 | HINT      | −0.0132 | Protein kinase C inhibitor                       |
| 1262  | Hs.7016   | RAB7      | −0.0362 | Rab 7 protein                                    |
| 0190  | Hs.184411 | ALB       | −0.0470 | Albumin                                          |
| 0948  | Hs.2795   | LDHA      | −0.0549 | Lactate dehydrogenase-A (LDHA)                   |
| 0502  | Hs.180532 | GPI       | −0.0575 | Hsp89                                           |
| 0152  | Hs.75410  | HSPA5     | −0.0640 | GRP78                                            |
| 1054  | Hs.74276  | CJC1      | −0.0686 | Nuclear chloride channel (RNCC protein)          |
| 0709  | Hs.253495 | SFTPD     | −0.0936 | Pulmonary surfactant protein D                   |
| 0867  | Hs.78996  | PCNA      | −0.0982 | PCNA                                             |
| 0165  | Hs.180414 | HSPA8     | −0.1014 | Heat shock cognate protein, 71 kDa               |
| 1109  | Hs.75103  | YWHAZ     | −0.1018 | 14-3-3 Δ                                         |
| 0137  | Hs.554    | SSA2      | −0.1032 | Ro/ss-A antigen                                  |
Protein and mRNA Correlation in Lung Adenocarcinomas

Table I—continued

| Spot | Unigene  | Gene name | r*   | Protein name                           |
|------|----------|-----------|------|----------------------------------------|
| 0278 | Hs.4112  | TCP1      | −0.1237 | T-complex protein I, α subunit          |
| 1769 | Hs.9614  | NPM1      | −0.1738 | B23/numatin                             |
| 0089 | Hs.74335 | HSPCB     | −0.2049 | Hsp90                                   |
| 2511 | Hs.153179| FABP5     | −0.2109 | E-FABP/FABP5                            |
| 1739 | Hs.16488 | CALR      | −0.2344 | Calreticulin 32                         |
| 1138 | Hs.301961| GSTM4     | −0.2438 | Glutathione S-transferase M4 (GST m4)  |
| 2533 | Hs.77060 | PSMB6     | −0.2512 | Macropain subunit Δ                    |

EXPERIMENTAL PROCEDURES

Tissues—Fifty-seven stage I and 19 stage III lung adenocarcinomas, as well as nine non-neoplastic lung tissue samples, were used for protein and mRNA analyses. Patient consent was obtained, and the project was approved by the Institutional Review Board. All tissues were obtained after resection at the University of Michigan Health System between May 1991 and July 1998. Tissues were all snap-frozen in liquid nitrogen and then stored at −80 °C. The patients included 46 females and 30 males ranging in age from 40.9 to 84.6 (average 63.8) years. Most patients (66/76) demonstrated a positive smoking history. Sixty-one tumor samples were classified as bronchial-derived, 14 were classified as bronchoalveolar, and one had a smoking history. Sixty-one tumor samples were classified as bronchiolar and non-neoplastic lung tissues. Protein levels were determined using quantitative 2D-PAGE analysis, and the separated protein polypeptides were identified using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The corresponding mRNA levels for the identified proteins within the same samples were determined using oligonucleotide microarrays. Correlation analyses showed that protein abundance is likely a reflection of the transcription for a subset of proteins, but translation and post-translational modifications also appear to influence the expression levels of many individual proteins in lung adenocarcinomas.

Non-neoplastic lung tissues. Protein levels were determined using quantitative 2D-PAGE analysis, and the separated protein polypeptides were identified using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The corresponding mRNA levels for the identified proteins within the same samples were determined using oligonucleotide microarrays. Correlation analyses showed that protein abundance is likely a reflection of the transcription for a subset of proteins, but translation and post-translational modifications also appear to influence the expression levels of many individual proteins in lung adenocarcinomas.

Mass Spectrometry and 2D Western Blotting—Preparative 2D gels were run using extracts from A549 lung adenocarcinoma cells (obtained from ATCC) and using the identical experimental conditions as the analytical 2D gels, except 30% more protein was loaded. The resolved protein gels were silver-stained using successive incubations in 0.02% sodium thiosulfate for 2 min, 0.1% silver nitrate for 40 min, and 0.014% formaldehyde plus 2% sodium carbonate for 10 min. For protein identification, protein polypeptides underwent trypsin digestion followed by MALDI-MS using a MALDI-TOF Voyager-DE mass spectrometer (Perseptive Biosystems, Framingham, MA). The masses were compared with known trypsin digest databases using the MS-FIT database (University of California, San Francisco; prospector.ucsf.edu/ucsfhtml3.2/msfit.htm). Some of the polypeptides included in the analysis had been identified prior to this study on the basis of sequencing (14). The identified protein spots used in this paper are shown in Fig. 1A. The method for 2D-PAGE Western blot verification was as described previously (15). The 2D Western blots of GRP58 and Op18 are shown in Fig. 1, C and E; the others, such as GRP78, GRP75, HSP70, HSC70, KRT8, KRT18, KRT19, Vimentin, ApoJ, 14–3–3, Annexin I, Annexin II, PGP9.5, DJ-1, GST-pi, and PGAM, are described elsewhere.2

Statistical Analysis—Missing values were replaced with the mean value of the protein spot. The transform x → log(1 + x) was applied to normalize all protein expression values. The relationship between protein and mRNA expression levels within the same samples was examined using the Spearman correlation coefficient analysis (16). To identify potentially significant correlations between gene and protein expression, we used an analytical strategy similar to SAM (significance analysis of microarrays) (17), which uses a permutation technique to determine the significance of changes in gene expression between different biological states. To obtain permuted correlation coefficients between gene and protein expression, genes were exchanged first in such a way that permuted correlation coefficient were calculated based on pseudo pairs of genes and proteins. The distribution of permuted correlation coefficients became stable after 60 permutations. This procedure was then repeated 60 times to obtain 60 sets of permuted correlation coefficients. For each of the 60 permutations, the correlations of genes and proteins were ranked were performed as described previously (12, 13). Our 2D-PAGE system allows us to run 20 gels at one time (one batch). Spot detection and quantification were accomplished utilizing Bio Image Visage System software (Bioimage Corp., Ann Arbor, MI). The integrated intensity of each spot was calculated as the measured optical density units × mm². Of the total possible 2000 spots detectable on each gel, 820 spots on the gel of each sample were matched using a Gel-ed match program with the same spots on a chosen “master” gel. In each sample, 250 ubiquitously expressed reference spots were used to adjust for variations between gels, such as that created by subtle differences in protein loading or gel staining. Slight differences because of batch were corrected after spot-size quantification.
| Spot | Unigene | Gene name | r* | Protein name |
|------|---------|-----------|----|--------------|
| 1494 | Hs.81915 | LAP18     | 0.4003 | OP18 (Stathmin) |
| 0057 | Hs.77899 | TPM1      | 0.3930 | Tropomyosins 1-5 |
| 0353 | Hs.289101 | GRP58     | 0.3802 | Protease disulfide isomerase (GRP58) |
| 0855 | Hs.169476 | GAPD      | 0.3930 | Glyceraldehyde-3-phosphate dehydrogenase |
| 1198 | Hs.41707 | HSPB3     | 0.3668 | Hsp27 |
| 1203 | Hs.83848 | TPI1      | 0.3395 | Triose phosphate isomerase (TPI) |
| 0523 | Hs.65114 | KRT18     | 0.3335 | Cytokeratin 18 |
| 1492 | Hs.81915 | LAP18     | 0.3234 | OP18 (Stathmin) |
| 1493 | Hs.75313 | AKR1B1    | 0.3154 | Aldose reductase |
| 1181 | Hs.78225 | ANXA1     | 0.3102 | Annexin variant I |
| 0438 | Hs.242463 | KRT8      | 0.3049 | Cytokeratin 8 |
| 0505 | Hs.297753 | VIM       | 0.2939 | Vimentin |
| 0593 | Hs.297753 | VIM       | 0.2939 | Vimentin |
| 1874 | Hs.75313 | AKR1B1    | 0.2790 | Aldose reductase |
| 0935 | Hs.75444 | YWHAH     | 0.2775 | 14-3-3 |η |
| 2524 | Hs.78225 | ANXA1     | 0.2612 | Annexin I |
| 2324 | Hs.65114 | KRT18     | 0.2601 | Cytokeratin 18 |
| 1192 | Hs.41707 | HSPB3     | 0.2558 | Hsp27 |
| 0350 | Hs.289101 | GRP58     | 0.2516 | Phospholipase C (GRP58) |
| 0992 | Hs.75313 | AKR1B1    | −0.2460 | Aldose reductase |
| 0861 | Hs.75313 | AKR1B1    | 0.0761 | Aldose reductase |
| 0853 | Hs.75313 | AKR1B1    | −0.0675 | Aldose reductase |
| 2503 | Hs.76392 | ALDH1     | −0.0565 | Aldehyde dehydrogenase |
| 0381 | Hs.76392 | ALDH1     | −0.0371 | Aldehyde dehydrogenase |
| 0371 | Hs.76392 | ALDH1     | −0.0680 | Aldehyde dehydrogenase |
| 1179 | Hs.78225 | ANXA1     | 0.2025 | Annexin variant I |
| 0762 | Hs.78225 | ANXA1     | −0.0739 | Annexin I |
| 0760 | Hs.78225 | ANXA1     | −0.0228 | Annexin I |
| 2324 | Hs.217493 | ANXA2     | 0.2223 | Lipocotin (annexin II) |
| 0772 | Hs.217493 | ANXA2     | 0.2080 | Lipocotin (annexin II) |
| 0734 | Hs.217493 | ANXA2     | 0.0701 | Lipocotin |
| 1239 | Hs.93194 | APOA1     | 0.1133 | Apolipoprotein A1 (ApoA1) |
| 1237 | Hs.93194 | APOA1     | −0.0373 | Apolipoprotein A1 (ApoA1) |
| 1234 | Hs.93194 | APOA1     | −0.0894 | Apolipoprotein A1 (ApoA1) |
| 0428 | Hs.25 | ATP5B     | 0.0080 | ATP synthase β subunit precursor |
| 0427 | Hs.25 | ATP5B     | 0.0122 | ATP synthase β subunit precursor |
| 0424 | Hs.25 | ATP5B     | −0.0992 | ATP synthase β subunit precursor |
| 0863 | Hs.75106 | CLU       | −0.0483 | Apolipoprotein J (ApoJ) |
| 0780 | Hs.75106 | CLU       | −0.0443 | Apolipoprotein J (ApoJ) |
| 1527 | Hs.119140 | EIF5A     | −0.0743 | eIF-5A |
| 1484 | Hs.119140 | EIF5A     | −0.0376 | eIF-5A |
| 1728 | Hs.5241 | FABP1     | −0.1916 | L-FABP |
| 1712 | Hs.5241 | FABP1     | −0.0473 | L-FABP |
| 0947 | Hs.169476 | GAPD     | 0.1745 | Glyceraldehyde-3-phosphate dehydrogenase |
| 1232 | Hs.75207 | GLO1      | 0.2249 | Glyoxalase-1 |
| 1229 | Hs.75207 | GLO1      | 0.0450 | Glyoxalase-1 |
| 1595 | Hs.158300 | HAP1     | −0.0137 | Huntingtin-associated protein 1 (neuroan 1) |
| 1810 | Hs.75990 | HP        | −0.4672 | α-Haptoglobin |
| 1459 | Hs.75990 | HP        | 0.0802 | α-Haptoglobin |
| 1458 | Hs.75990 | HP        | −0.0305 | α-Haptoglobin |
| 0619 | Hs.75990 | HP        | 0.0461 | B-haptoglobin |
| 0615 | Hs.75990 | HP        | −0.0034 | B-haptoglobin |
| 1250 | Hs.41707 | HSPB3     | −0.1024 | Hsp27 |
| 0549 | Hs.79037 | HSPD1     | 0.1074 | Hsp60 |
| 0338 | Hs.79037 | HSPD1     | 0.2265 | Hsp60 |
| 0333 | Hs.79037 | HSPD1     | 0.1383 | Hsp60 |
| 0331 | Hs.79037 | HSPD1     | 0.1603 | Hsp60 |
| 2381 | Hs.65114 | KRT18     | 0.2016 | Cytokeratin 18 |
| 0535 | Hs.65114 | KRT18     | 0.1106 | Cytokeratin 18 |
Protein and mRNA Correlation in Lung Adenocarcinomas

TABLE II—continued

| Spot | Unigene | Gene name | r* | Protein name |
|------|---------|-----------|----|--------------|
| 0529 | Hs.65114 | KRT18     | 0.1279 | Cytokeratin 18 |
| 0528 | Hs.65114 | KRT18     | 0.0414 | Cytokeratin 18 |
| 0527 | Hs.65114 | KRT18     | 0.0436 | Cytokeratin 18 |
| 0514 | Hs.65114 | KRT18     | 0.0733 | Cytokeratin 18 |
| 0451 | Hs.242463 | KRT8     | −0.0111 | Cytokeratin 8 |
| 0446 | Hs.242463 | KRT8     | 0.0347 | Cytokeratin 8 |
| 0444 | Hs.242463 | KRT8     | −0.1311 | Cytokeratin 8 |
| 0443 | Hs.242463 | KRT8 | 0.0942 | Cytokeratin 8 |
| 1488 | Hs.81915 | LAP18 | 0.0495 | OP18 (Statmin) |
| 0321 | Hs.75655 | P4HB | −0.0546 | PDI (proly-4-OH-B) |
| 0320 | Hs.75655 | P4HB | −0.0041 | PDI (proly-4-OH-B) |
| 1063 | Hs.75323 | PHB | 0.0441 | Prohibitin |
| 0837 | Hs.75323 | PHB | 0.1402 | Prohibitin |
| 0326 | Hs.297681 | SERPINA1 | −0.0227 | α-1-Antitripsin |
| 0322 | Hs.297681 | SERPINA1 | −0.0277 | α-1-Antitripsin |
| 0241 | Hs.297681 | SERPINA1 | −0.0148 | α-1-Antitripsin |
| 1280 | Hs.301254 | SFTPA1 | −0.1488 | Pulmonary surfactant-associated protein |
| 1278 | Hs.301254 | SFTPA1 | −0.2040 | Pulmonary surfactant-associated protein |
| 0866 | Hs.73980 | TNNT1 | 0.1162 | Troponin T |
| 0778 | Hs.73980 | TNNT1 | 0.0740 | Troponin T |
| 1213 | Hs.83848 | TPI1 | 0.0024 | Triose phosphate isomerase (TPI) |
| 1210 | Hs.83848 | TPI1 | 0.0490 | Triose phosphate isomerase (TPI) |
| 1207 | Hs.83848 | TPI1 | −0.1615 | Triose phosphate isomerase (TPI) |
| 1204 | Hs.83848 | TPI1 | 0.0209 | Triose phosphate isomerase (TPI) |
| 1202 | Hs.83848 | TPI1 | 0.0721 | Triose phosphate isomerase (TPI) |
| 1161 | Hs.83848 | TPI1 | 0.2265 | Triose phosphate isomerase (TPI) |
| 1052 | Hs.77899 | TPM1 | −0.1040 | Tropomyosin clean-product |
| 1039 | Hs.77899 | TPM1 | −0.2999 | Cytoskeletal tropomyosin |
| 1035 | Hs.77899 | TPM1 | −0.3821 | Tropomyosin |
| 0783 | Hs.77899 | TPM1 | 0.0757 | Tropomyosins 1–5 |
| 1574 | Hs.194366 | TTR | −0.0065 | Transthyretin |
| 0809 | Hs.194366 | TTR | 0.0399 | Transthyretin multimer |
| 2202 | Hs.76118 | UCHL1 | −0.0220 | Ubiquitin carboxyl-terminal hydrolase isozyme L1 |
| 1246 | Hs.76118 | UCHL1 | −0.1261 | Ubiquitin carboxyl-terminal hydrolase isozyme L1 |
| 1242 | Hs.76118 | UCHL1 | 0.1473 | Ubiquitin carboxyl-terminal hydrolase isozyme L1 |
| 0506 | Hs.297753 | VIM | 0.0951 | Vimentin |
| 0594 | Hs.297753 | VIM | −0.2664 | Vimentin-derived protein (vid4) |
| 0508 | Hs.297753 | VIM | 0.1008 | Vimentin-derived protein (vid2) |
| 0419 | Hs.297753 | VIM | 0.0032 | Vimentin-derived protein (vid1) |
| 1279 | Hs.75544 | YWHAH | 0.0059 | 14-3-3 η |

such that $p_i$ denotes the i-th largest correlation coefficient for j-th permutation. Hence, the expected correlation coefficient, $p_i$, was the average over the 60 permutations, $p_i = \Sigma_{j=1}^{60} p_{ij}/60$. A scatter plot of observed correlations ($\rho_i$) versus the expected correlations is shown in Fig. 2D. For this study, we chose threshold $\Delta = 0.115$ so that correlation would be considered significant if absolute value of difference between $\rho_i$ and $p_i$ was greater than the threshold. Twenty-nine (including one with observed correlation coefficient $-0.4672$) of 165 pairs of gene and protein expression were called significant in such criteria, and the permuted data generated an average of 5.1 falsely significant pairs of gene and protein expression. This provided an estimated false discovery rate (the percentage of pairs of gene and protein expression identified by chance) for our data set.

RESULTS

Correlation of Individual Proteins and mRNA Expression within Each Tumor—We have examined quantitatively 165 protein spots on 2D gels representing 98 genes and compared protein levels with mRNA levels for a cohort of 85 lung adenocarcinomas and normal lung samples. Of the 165 protein spots, 69 proteins were represented by only one known spot on 2D gels for an individual gene, whereas 96 protein spots showed multiple protein products from 29 different genes. 2D Western blotting verified the proteins identified by mass spectrometry when specific antibodies were available. Spearman correlation coefficients of the proteins and their associated mRNA for each protein spot were generated using all 76 lung adenocarcinomas and nine non-neoplastic lung tissues (see Tables I and II, and see Figs. 1 and 2). The correlation coefficients ($r$) ranged from $-0.467$ to 0.442 (Fig. 2D). A total of 28 protein spots (21 genes) were found to have a statistically significant correlation between expression of
their protein and mRNA ($r > 0.2445; p < 0.05$). This accounts for 17% (28/165) of the 165 protein spots. Among the 69 genes for which only a single protein spot was known (Table I), nine genes (9/69, 13%) were observed to show a statistically significant relationship between protein and mRNA abundance ($r > 0.2445; p < 0.05$). The proteins whose expression levels were correlated with their mRNA abundance included those involved in signal transduction, carbohydrate metabolism, apoptosis, protein post-translational modification, structural proteins, and heat shock proteins (Table III).

**Individual Isoforms of the Same Protein Have Different Protein/mRNA Correlation Coefficients**—Of the 165 protein spots, 96 represent protein products of 29 genes with at least two isoforms. Among these 96 protein spots, 19 (19/96 protein spots, 20%) showed a statistically significant correlation between their protein and mRNA expression ($r > 0.2445; p < 0.05$) (Table II) and represented 12 genes (12/29, 41%). Individual isoforms of the same protein demonstrated different protein/mRNA correlation coefficients. For example, 2D-PAGE/Western analysis revealed four isoforms of OP18 differing in regards to isoelectric point but similar in molecular weight. Three of the four isoforms (spots 1492, 1493, and 1494) showed a statistically significant correlation between their protein and mRNA abundance ($r = 0.3234, 0.3154, and 0.4003$, respectively). The forth isoform (spot 1488) showed no correlation between protein and mRNA expression ($r = 0.0495$). Similarly, just one of five quantified isoforms of cytokeratin 8 (spot 439) demonstrated a statistically significant correlation between protein and mRNA abundance ($r = 0.3049; p < 0.05$) (Table II).

In addition to differences in the relationship between mRNA levels and protein expression among separate isoforms, some genes with very comparable mRNA levels showed a 24-fold difference in their protein expression. Genes with comparable protein expression levels also showed up to a 28-fold variance in their mRNA levels.

**Lack of Correlation for mRNA and Protein Expression when Using Average Tumor Values across All 165 Protein Spots (98 Genes)**—The relationship between mRNA and protein expression was also examined by using the average expression values for all samples. To analyze this relationship using this approach, the average value for each protein or mRNA was generated using all 85 lung tissue samples. The range of normalized average protein values ranged from $0.0646$ to $0.0979$ (raw value 0.0036 to 4.1947), and the range for mRNA was from 0 to 15260.5 for all 165 individual protein spots. The Spearman correlation coefficient for the whole data set (165 protein spots/98 genes) was $-0.025$ (Fig. 3A). Even for the 28 protein spots (Fig. 2D) that were found to have a statistically significant correlation between their mRNA and protein, use of
the average value resulted in a correlation coefficient value of 
−0.035, which was not significant (Fig. 3B).

Lack of a Relationship between Protein/mRNA Correlation Coefficients and Average Protein Abundance—To determine whether an absolute protein level might influence the correlation with mRNA, the mean value of each protein (relative abundance) and the Spearman protein/mRNA correlation coefficients among all 85 samples were examined. No relationship between the protein abundance and the correlation coefficients was observed \( (r = 0.039; p > 0.05) \). A detailed analysis of separate subsets of proteins with differing levels of abundance (less than \( -0.0014 \), larger than \( -0.0014 \), or larger than \( 0.0077 \)) also showed a lack of correlation between mRNA and protein expression among the 83 (50%), 82 (50%), and 41 (25%) of 165 total protein spots, respectively \( (r = 0.016, 0.08, \) and 0.172, respectively).

Stage-related Changes in the Protein/mRNA Correlation Coefficients—To determine whether the 21 genes (28 protein spots) showing a significant correlation between the protein and mRNA expression among all samples demonstrate changes in this relationship during tumor progression, the correlations were examined separately for stage I \( (n = 57) \) and stage III \( (n = 19) \) lung adenocarcinomas (Table III). The number of non-neoplastic lung samples \( (n = 9) \) was insufficient for a separate correlation analysis of this group. Many of the protein spots represent one of several known protein isoforms for a given gene. The majority of genes (16/21) did not differ in the protein/mRNA correlation between stage I and stage III tumors indicating a similar regulatory relationship between the mRNA and protein spot. GRP-58, PSMC, SOD1, TPI1, and VIM, however, were found to demonstrate significant differences in the correlation coefficients between stage I and stage III lung adenocarcinomas. For GRP-58, PSMC, and VIM the change in the correlation coefficient was because of a relative increase in protein expression in stage III tumors. For SOD and TPI the change resulted from a relative decrease in expression of this specific protein in stage III tumors.

DISCUSSION

Relatively little is known about the regulatory mechanisms controlling the complex patterns of protein abundance and post-translational modification in tumors. Most reports concerning the regulation of protein translation have focused on
Protein and mRNA Correlation in Lung Adenocarcinomas

Table III

| Spot | Gene name | r (Stage I) | r (Stage III) | Function |
|------|-----------|-------------|---------------|----------|
| 1874 | AKR1B1    | 0.269       | 0.106         | Carbohydrate metabolism; electron transporter |
| 2524 | ANXA1     | 0.184       | 0.572         | Phospholipase inhibitor; signal transduction |
| 0994 | ANXA4     | 0.660       | 0.362         | Phospholipase inhibitor |
| 0963 | ANXA5     | 0.241       | 0.390         | Phospholipase inhibitor; calcium binding; phospholipid binding |
| 1314 | DJ-1      | 0.363       | 0.354         | Signal transduction |
| 1405 | FTL       | 0.126       | 0.358         | Iron storage protein |
| 0855 | GAPD      | 0.243       | 0.581         | Carbohydrate metabolism (glycolysis regulation) |
| 0350 | GRP58     | 0.327       | -0.087        | Signal transduction; protein disulfide isomerase |
| 0264 | HNRPK     | 0.360       | 0.243         | RNA-binding protein (RNA processing/modification) |
| 1192 | HSPB3     | 0.457       | 0.633         | Heat shock protein |
| 0523 | KRT18     | 0.115       | 0.371         | Structural protein |
| 0439 | KRT8      | 0.323       | 0.436         | Structural protein |
| 1492 | LAP18     | 0.483       | 0.663         | Signal transduction; cell growth and maintenance |
| 1638 | LGALS1    | 0.200       | 0.528         | Apoptosis; cell adhesion; cell size control |
| 1252 | PSMC      | 0.253       | 0.060         | Protein degradation |
| 1104 | SFN       | 0.485       | 0.475         | Signal transduction (protein kinase C inhibitor) |
| 1454 | SOD1      | 0.352       | 0.079         | Oxidoreductase |
| 1203 | TPH       | 0.378       | 0.009         | Carbohydrate metabolism |
| 0957 | TPM1      | 0.475       | 0.225         | Structural protein (muscle); control of heart |
| 0935 | VIM       | 0.054       | 0.556         | Structural protein |
| 0935 | YWHAH     | 0.283       | 0.210         | Signal transduction |

one or several protein products (18). Celis et al. (19) found a good correlation between transcript and protein levels among 40 well resolved, abundant proteins using a proteomic and microarray study of bladder cancer. By comparing the mRNA and protein expression levels within the same tumor samples, we found that 17% (28/165) of the protein spots (21/98 genes) show a statistically significant correlation between mRNA and protein. These proteins appear to represent a diverse group of gene products and include those involved in signal transduction, carbohydrate metabolism, protein modification, cell structure, heat shock, and apoptosis. These results suggest that expression of this subset of 165 proteins is likely to be regulated at the transcriptional level in these tissues. The majority of the protein isoforms, however, did not correlate with mRNA levels, and thus their expression is regulated by other mechanisms. We also observed a subset of proteins that demonstrated a negative correlation with the mRNA expression values; for example α-haptoglobin demonstrated a strong negative correlation with its mRNA expression values. This may reflect negative feedback on the mRNA or the protein or the presence of other regulatory influences that are not understood currently.

Post-translational modification or processing will result in individual protein products of the same gene migrating to different locations on 2D-PAGE gels (20). Because the identity of all possible isoforms for each protein examined has not been characterized completely, this may influence the correlation analyses performed in this study. This is partly because of limitations of the 2D-PAGE and mass spectrometry technologies (21, 22). Potential inconsistencies between mRNA and protein correlations that have been reported may also be because of differences, even in the same gene, in the mechanisms of protein translation among different cells or as measured in different laboratories (23).

In this study, we examined 165 protein spots identified in lung adenocarcinomas. Ninety-six protein spots, representing the products of 29 genes, contained at least two protein isoforms. Nineteen of 96 protein spots, representing 12 genes, were shown to have a statistically significant correlation between their protein and mRNA expression, suggesting that the levels of these proteins reflects the transcription of the corresponding genes. Differences in protein/mRNA correlations were found among the individual isoforms of a given protein. For example, of the four OP18 isoforms, three showed a statistically significant correlation between the protein and mRNA expression levels. The lack of relationship for the one isoform, however, indicates that individual protein isoforms of the same gene product can be regulated differentially. This is not unexpected and likely reflects other post-translational mechanisms that can influence isoform abundance in tissues and cancer.

In addition to the analyses of the correlation of mRNA/protein within the same tumor samples, we also tested the global relationship between mRNA and the corresponding protein abundance across all 165 protein spots in the lung samples. A protein and mRNA average value for each gene was generated using all 85 lung tissues samples. We observed a very wide range of normalized average protein and mRNA values. The correlation coefficient generated using this average value data set was −0.025, and even for the 28 protein spots that showed a statistically significant correlation between individual mRNA and proteins, the correlation value was only −0.035. This suggests that it is not possible to predict overall protein expression levels based on average
mRNA abundance in lung cancer samples. This conclusion is also supported by previous results from Anderson and Seilhamer (24), who examined 19 genes in human liver cells, and by Gygi et al. (25), who examined 106 genes in yeast. Both studies found a lack of correlation between mRNA and protein expression when average or overall levels were used.

A good correlation was reported when the 11 most abundant proteins were examined in yeast (25), suggesting that the level of protein abundance may be a factor that may influence the correlation between mRNA and protein. In the present study, a fairly wide range of mean protein values among 165 protein spots in lung adenocarcinomas was observed, and the correlation coefficients also varied from −0.467 to 0.442.

A comparison between the mean value of each protein and the correlation coefficient generated using all 85 tissue samples did not reveal a strong relationship between the overall protein abundance and the correlation coefficients (r = 0.039; p > 0.05). Detailed analysis of different subsets of protein abundance also failed to show a correlation between mRNA and protein expression. Thus in contrast to yeast, a relationship between mRNA/protein correlation coefficient and protein abundance in human lung adenocarcinomas was not observed.

The results of this study indicate that the level of protein abundance in lung adenocarcinomas is associated with the corresponding levels of mRNA in 17% (28 proteins) of the total 165 protein spots examined. This was substantially
higher than the amount predicted to result by chance alone (which was 5.1) and suggests that a transcriptional mechanism likely underlies the abundance of these proteins in lung adenocarcinomas. We also demonstrate that the expression of individual isoforms of the same protein may or may not correlate with the mRNA, indicating that separate and likely post-translational mechanisms account for the regulation of isoform abundance. These mechanisms may also account for the differences in the correlation coefficients observed between stage I and stage III tumors, indicating that specific protein isoforms show regulatory changes during tumor progression.

Further studies in lung adenocarcinomas will examine the relationship between the expression of individual protein isoforms and specific clinical-pathological features of these tumors, such as the presence of angiolymphatic invasion, and nodal or pleural surface involvement. The potential to identify specific protein isoforms associated with biological behavior in lung adenocarcinomas would be of considerable interest and will add to our understanding of the regulation of gene products by transcriptional, translational, and post-translational mechanisms.

Acknowledgments—We thank Kerby A. Shedden, Rork D. Kuick, Eric Puravs, Robert Hinderer, Melissa C. Krause, and Christopher Wood for assistance in this study.

* This work was supported by NCI, National Institutes of Health Grant U19 CA-85953. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡‡ To whom correspondence should be addressed: General Thoracic Surgery, SRB II, B650, Box 0686, University of Michigan Medical School, Ann Arbor, MI 48109-086; E-mail: dgbeer@umich.edu.

REFERENCES

1. Ideker, T., Thorsson, V., Ranish, J. A., Christmas, R., Buhler, J., Eng, J. K., Bumgarner, R., Goodlett, D. R., Aebersold, R., Hood, L. (2001) Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292, 929–934

2. Liang, P., Pardee, A. B. (1998) Differential display. A general protocol. Mol. Biotechnol. 10, 261–267

3. Porter, D. A., Krop, I. E., Nasser, S., Sgroi, D., Kaelin, C. M., Marks, J. R., Riggins, G., Polyak, K. (2001) A sage (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 61, 5697–5702

4. Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., Samps, N., Dougherty, E., Wang, E., Marincola, F., Gooden, C., Luedens, J., Gilletfeter, A., Pollock, P., Carpten, J., Gillanders, E., Leja, D., Dietrich, K., Beaudry, C., Berens, M., Alberts, D., Sondak, V. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536–540

5. Fung, E. T., Wright, G. L., Jr., Dalmasso, E. A. (2000) Proteomic strategies for biomarker identification: progress and challenges. Curr. Opin. Mol. Ther. 2, 643–650

6. Davidson, D., Baldwin, R. (2001) Bioinformatics beyond sequence: mapping gene function in the embryo. Nat. Rev. Genet. 2, 409–417

7. Chee, M., Yang, R., Hubbell, E., Bero, A., Huang, X. C., Stern, D., Winkler, J., Lockhart, D. J., Morris, M. S., Fodor, S. P. (1996) Accessing genetic information with high-density DNA arrays. Science 274, 610–614

8. Wang, D. G., Fan, J. B., Siao, C. J., Berno, A., Young, P., Sapolsky, R., Ghandour, G., Perkins, N., Winchester, E., Spencer, J., Kruglyak, L., Stein, L., Heie, L., Topaloglou, T., Hubbell, E., Robinson, E., Mittmann, M., Morris, M. S., Shen, N., Kilburn, D., Rioux, J., Nusbaum, C., Rozen, S., Hudson, T. J., Lander, E. S. (1998) Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 280, 1077–1082

9. Pease, A. C., Solas, D., Sullivan, E. J., Cronin, M. T., Holmes, C. P., Fodor, S. P. (1994) Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc. Natl. Acad. Sci. U. S. A. 91, 5022–5026

10. Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., Loda, M., Weber, G., Mark, E. J., Lander, E. S., Wong, W., Johnson, B. E., Golub, T. R., Sugarbaker, D. J., Meyerson, M. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U. S. A. 98, 13790–13795

11. Giordano, T. J., Shedden, K. A., Schwartz, D. R., Kuick, R., Taylor, J. M. G., Lee, N., Misek, D. E., Greenesn, J. K., Kardia, S. L. D., Beer, D. G., Rennert, G., Cho, K. R., Gruber, S. B., Fearon, E. R., Hanash, S. (2001) Organ-specific molecular classification of lung, colon and ovarian adenocarcinomas using gene expression profiles. Am. J. Pathol. 159, 1231–1238

12. Strahler, J. R., Kuick, R., Hanash, S. M. (1989) In Protein Structure: A Practical Approach (Creighton, T., ed) pp. 65–92, IRL Press, Oxford

13. Merril, C. R., Dunau, M. L., Goldman, D. (1981) A rapid sensitive silver stain for polypeptides in polyacrylamide gels. Anal. Biochem. 101, 201–207

14. Hanash, S. M., Strahler, J. R., Chan, Y., Kuick, R., Teichroew, D., Neel, J. V., Halait, N., Keim, D. R., Gratiot-Deans, J., Ungar, D., Richardson, B. C. (1993) Data base analysis of protein expression patterns during T-cell ontogeny and activation. Proc. Natl. Acad. Sci. U. S. A. 90, 3314–3318

15. Brichory, F. M., Misek, D. E., Yin, A. M., Krause, M. C., Giordano, T. J., Biddison, W. E., Hanash, S. M. (1996) An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. U. S. A. 93, 9824–9829

16. Lavers-Phillips, S. E., MacGilavran, D. W., Jr. (2000) The tyrosine kinases p53/p56lyn and p72fynk are differentially expressed at the protein level but not at the messenger RNA level in nonreleasing human basophils. Am. J. Respir. Cell Mol. Biol. 23, 566–571

17. Tusher, V. G., Tibshirani, R., Chu, G. (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U. S. A. 98, 5116–5121

18. Tew, K. D., Monks, A., Barone, L., Rossier, D., Akerman, G., Montali, J. A., Wheatley, J. B., Schmidt, D. E., Jr. (1996) Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol. Pharmacol. 50, 149–159

19. Caron, J. E., Kruhoffer, M., Gromov, I., Frederiksen, C., Ostergaard, M., Thykjaer, T., Gromov, P., Yu, J., Palsdottir, H., Magnusson, N., Orntoft, T. F. (2000) Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett. 480, 2–16

20. Anderson, N. L., Anderson, N. G. (1998) Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 19, 1853–1861

21. Gygi, S. P., Corhais, G. L., Zhang, Y., Rochon, Y., Aebersold, R. (2000) Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc. Natl. Acad. Sci. U. S. A. 97, 9390–9395

22. Fey, S. J., Larsen, P. M. (2001) 2D or not 2D. Two-dimensional gel electrophoresis. Curr. Opin. Chem. Biol. 5, 26–33

23. McBride, S., Walsh, D., Mealey, P., Daly, N., Clynne, M. (1999) Bromodeoxyuridine induces keratin protein synthesis at a posttranscriptional level in human lung tumor cell lines. Differentiation 64, 185–193

24. Anderson, L. N., Selheim, J. (1997) A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18, 533–537

25. Gygi, S. P., Rochon, Y., Franca, B. R., Aebersold, R. (1999) Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19, 1720–1730